Search results for "Drug Compounding"

showing 10 items of 90 documents

Pharmacokinetics of oligodeoxynucleotides encapsulated in liposomes: effect of lipid composition and preparation method

2000

1. The effect of the method employed to prepare liposomes and their lipid composition were evaluated in terms of the encapsulation efficiency and pharmacokinetic features of two oligodeoxynucleotides of a 21 mer: the normal (N-Odn) and the phosphorothioate (S-Odn) oligodeoxynucleotide. 2. Liposomes were prepared by the classical method of multilamellar vesicles (MV) and by the dehydration-rehydration method (DR). Two lipid mixtures were used to prepare liposomes--the predominant lipid being phosphatidylcholine (PC) and sphingomyelin (SM) respectively. 3. The DR method for liposome preparation provided the highest encapsulation efficiency, regardless of liposome lipid composition and the typ…

Drug CompoundingHealth Toxicology and MutagenesisLipid compositionMultilamellar vesiclesToxicologyBiochemistryPreparation methodMicechemistry.chemical_compoundPharmacokineticsPhosphatidylcholineAnimalsPharmacologyPlasma clearanceLiposomeChromatographyChemistryhemic and immune systemsGeneral MedicineThionucleotidesrespiratory systemLipidsOligodeoxyribonucleotidesBiochemistryInjections IntravenousLiposomesSphingomyelinXenobiotica
researchProduct

Predictability of drug encapsulation and release from propylene carbonate/PLGA microparticles.

2020

Abstract Key parameters for microparticle-based parenteral depot formulation development are entrapment efficiency and sustained drug release, which both depend on the intermolecular affinity of the components. Here, partial solubility parameters were evaluated as descriptors for 21 drug substances and 3 polymers in propylene carbonate (PC). Out of these 21 drug substances, eight BCS class II substances (celecoxib, clotrimazole, erythromycin, ibuprofen, indomethacin, itraconazole, lopinavir and ritonavir) were encapsulated using PLGA (Poly(DL-lactide-co-glycolide)) as polymer matrix and PC as a polar aprotic solvent in order to assign microparticle properties to potential affinity-related i…

Drug CompoundingPharmaceutical Science02 engineering and technology030226 pharmacology & pharmacy03 medical and health scienceschemistry.chemical_compoundPropane0302 clinical medicinePolylactic Acid-Polyglycolic Acid CopolymermedicineLactic AcidMicroparticleSolubilityParticle SizeChemistry021001 nanoscience & nanotechnologyIbuprofenMicrospheresSolventHildebrand solubility parameterPLGAChemical engineeringPharmaceutical PreparationsSolubilityPropylene carbonate0210 nano-technologyGlass transitionPolyglycolic Acidmedicine.drugInternational journal of pharmaceutics
researchProduct

Microparticle preparation by a propylene carbonate emulsification-extraction method

2018

Abstract The use of various harmful organic solvents for microparticle formulations is still widespread. Here, an alternative low toxicity solvent (propylene carbonate; PC) is proposed for the preparation of poly(lactic-co-glycolic-acid) (PLGA) microparticles. Based on the classical emulsification-solvent extraction methodology, the use of PC offers the unique advantage of an additional solvent extraction step using hydrolytic solvent cleavage during microparticle preparation. Spherical, rough-surfaced microparticles were obtained with a volume median diameter range from 20 to 60 µm. The residual PC content has been identified to be the major factor for the solidification hindrance, leading…

Drug CompoundingPolysorbatesPharmaceutical Science02 engineering and technology010402 general chemistry01 natural sciencesPropanechemistry.chemical_compoundHydrolysisPolylactic Acid-Polyglycolic Acid CopolymerLactic AcidMicroparticleLow toxicityExtraction (chemistry)021001 nanoscience & nanotechnology0104 chemical sciencesSolventPLGAchemistryChemical engineeringPropylene carbonateSolventsEmulsionsExtraction methods0210 nano-technologyPolyglycolic AcidInternational Journal of Pharmaceutics
researchProduct

Novel yeast extract is superior to colloidal oatmeal in providing rapid itch relief

2020

Background Approximately, 13.5% of the population suffers from chronic itch. Many cosmetic and pharmaceutical treatments for itch are available; however, cosmetic treatments are not reliably effective and most pharmaceutical formulations carry the risk of adverse events with chronic use. Aims Previously, we have reported a novel extraction process of Saccharomyces cerevisiae, that is, Baker's yeast. The extract obtained from the novel process demonstrates superior anti-itch properties compared to other yeast extracts. In our previous study, we demonstrated that, after 30 minutes, the extract significantly reduced itch when compared to a placebo lotion (P = .002). Methods In the present stud…

Drug CompoundingPopulationMarket leaderSaccharomyces cerevisiaeDermatology030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineDouble-Blind Methodchronic effect ; cosmetic ; pruritisotorhinolaryngologic diseasesHumansYeast extractMedicineskin and connective tissue diseaseseducationColloidal oatmealeducation.field_of_studyEmollientsTraditional medicinebusiness.industryPruritusSignificant differenceItch ReliefYeast030220 oncology & carcinogenesisLotionbusinessJournal of Cosmetic Dermatology
researchProduct

Cross‐sectional comparative study of pharmacokinetics and efficacy between sucrose‐formulated recombinant factor VIII (Kogenate ® ) and BAY 81‐8973 (…

2019

Drug compoundingmedicine.medical_specialtyCross-sectional studybusiness.industryTreatment outcomeHematologyGeneral MedicineModerate haemophilia ARecombinant factor viiiPharmacokineticsInternal medicinemedicineIn patientYoung adultbusinessGenetics (clinical)Haemophilia
researchProduct

5-Fluorouracil Buccal Tablets for Locoregional Chemotherapy of Oral Squamous Cell Carcinoma: Formulation, Drug Release and Histological Effects on Re…

2010

5-Fluorouracil (5-FU) is currently used for treatment of oral squamous cell carcinoma (OSCC). 5-FU is given by i.v. although the systemic administration is associated with severe toxic effects and no topical formulations of 5-FU for buccal drug delivery have been reported. In this study we would report the development of buccal tablets suitable for direct application of low-doses of 5-FU on cancer lesions. The topical administration could be effective on tumor area while systemic undesired side effects are avoided. Preliminarily, the limited tendency of 5-FU to cross the buccal tissue was established using reconstituted human oral epithelium (RHOE, in vitro) and porcine buccal mucosa (ex vi…

DrugAntimetabolites AntineoplasticPathologymedicine.medical_specialtySwineChemistry PharmaceuticalDrug Compounding5-Fluorouracilmedia_common.quotation_subjectPharmaceutical ScienceApoptosisSettore MED/08 - Anatomia PatologicaLocoregional drug deliveryOral Squamous Cell CarcinomaPermeabilityTissue Culture TechniquesDrug Delivery SystemsSettore MED/28 - Malattie OdontostomatologicheCarcinomaAnimalsHumansMedicinemedia_commonbusiness.industryMouth MucosaAdministration BuccalCancerBuccal administrationmedicine.diseaseReconstituted Human Oral Epitheliumstomatognathic diseasesSettore CHIM/09 - Farmaceutico Tecnologico ApplicativoFluorouracilDrug deliveryCarcinoma Squamous CellSystemic administrationMouth NeoplasmsFluorouracilPorcine buccal mucosaBuccal tabletsbusinessEx vivoTabletsmedicine.drugCurrent Drug Delivery
researchProduct

Effect of thickener on disintegration, dissolution and permeability of common drug products for elderly patients

2019

Dysphagia is a very common problem suffered by elderly patients. The use of thickeners during administration in these patients helps to prevent difficulties with swallowing larger solid dosage forms. However, there are several indications when the thickeners may influence disintegration and dissolution processes of solid dosage forms, potentially affecting therapeutic efficacy. In this paper the effects of a commonly used thickener on tablet disintegration, dissolution and subsequent absorption of 6 formulated drugs frequently used in elderly patients (Aspirin, Atenolol, Acenocumarol, Candesartan, Ramipril and Valsartan) in two different administration conditions (intact tablet and crushed …

DrugDrug Compoundingmedia_common.quotation_subjectPharmaceutical Science02 engineering and technologyPharmacology030226 pharmacology & pharmacyPermeabilityDosage form03 medical and health sciences0302 clinical medicinemedicineAnimalsHumansIn patientDissolution testingRats WistarDissolutionAgedmedia_commonViscosityChemistryGeneral Medicine021001 nanoscience & nanotechnologyAtenololRatsDrug LiberationSolubilityPermeability (electromagnetism)Deglutition Disorders0210 nano-technologyTabletsBiotechnologymedicine.drugEuropean Journal of Pharmaceutics and Biopharmaceutics
researchProduct

Phospholipid-polyaspartamide micelles for pulmonary delivery of corticosteroids

2011

A novel drug delivery system for beclomethasone dipropionate (BDP) has been constructed through self-assembly of a pegylated phospholipid-polyaminoacid conjugate. This copolymer was obtained by chemical reaction of α,β-poly(N-2-hydroxyethyl)-DL-aspartamide (PHEA) with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethyleneglycol)2000] (DSPE-PEG(2000)-NH(2)). Benefiting from the amphiphilic structure with the hydrophilic shell based on both PHEA and PEG and many hydrophobic stearoyl tails, PHEA-PEG(2000)-DSPE copolymer was able to self assemble into micelles in aqueous media above a concentration of 1.23 × 10(-7)M, determined by fluorescence studies. During the self-assembling …

ErythrocytesBiocompatibilityCell SurvivalDrug CompoundingDrug StorageALPHABETA-Poly(N-2-hydroxyethyl)-dl- aspartamide (PHEA) 12-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethyleneglycol)2000](DSPE-PEG2000-NH2) Polymeric micelles Drug delivery Beclomethasone dipropionate (BDP) Pulmonary diseasesPhospholipidPharmaceutical Science[object Object]HemolysisMicelleCell LinePolyethylene Glycolschemistry.chemical_compoundDrug StabilityAmphiphilePEG ratioPulmonary diseasesHumans?Beclomethasone dipropionate (BDP)Particle SizeLungMicellesDrug CarriersChromatographyAqueous solutionMolecular StructureChemistryPhosphatidylethanolaminesBeclomethasonetechnology industry and agriculture?-Poly(N-2-hydroxyethyl)-dl-aspartamide (PHEA)Spectrometry FluorescenceSolubilitySettore CHIM/09 - Farmaceutico Tecnologico ApplicativoDrug deliveryDrug deliveryPolymeric micellesNanocarriersPeptidesHydrophobic and Hydrophilic InteractionsNuclear chemistry
researchProduct

Dual Enzyme-Responsive Capsules of Hyaluronic Acid-block-Poly(Lactic Acid) for Sensing Bacterial Enzymes.

2015

The synthesis of novel amphiphilic hyaluronic acid (HYA) and poly(lactic acid) (PLA) block copolymers is reported as the key element of a strategy to detect the presence of pathogenic bacterial enzymes. In addition to the formation of defined HYA-block-PLA assemblies, the encapsulation of fluorescent reporter dyes and the selective enzymatic degradation of the capsules by hyaluronidase and proteinase K are studied. The synthesis of the dual enzyme-responsive HYA-b-PLA is carried out by copper-catalyzed Huisgen 1,3-dipolar cycloaddition. The resulting copolymers are assembled in water to form vesicular structures, which are characterized by scanning electron microscopy, transmission electron…

Fluorescence-lifetime imaging microscopyStaphylococcus aureusMaterials sciencePolymers and PlasticsCell SurvivalPolymersDrug CompoundingPolyestersMolecular Sequence DataPrimary Cell CultureHyaluronoglucosaminidaseBiosensing TechniquesFluorescence spectroscopyNanocapsuleschemistry.chemical_compoundDynamic light scatteringBacterial ProteinsNanocapsulesHyaluronidaseAmphiphileMaterials ChemistrymedicineHumansLactic AcidHyaluronic AcidMicellesFluorescent DyesCycloaddition ReactionRhodaminesOrganic Chemistrytechnology industry and agricultureEndothelial CellsDermisLactic acidchemistryBiochemistryCarbohydrate SequencePseudomonas aeruginosaBiophysicsLiberationEndopeptidase Kmedicine.drugMacromolecular rapid communications
researchProduct

Implementation and microbiological stability of dose-banded ganciclovir infusion bags prepared in series by a robotic system.

2018

Objectives The implementation of dose-banding (DB) in centralised, pharmacy-based cytotoxic drug preparation units allows the preparation of standardised doses in series. The aim of this study was to evaluate the feasibility of DB for the prescribing of ganciclovir (GV) infusion solutions and to investigate the microbiological stability of dose-banded, automatically prepared ready-to-administer GV infusion bags by media-fill simulation tests and sterility tests. Methods The frequency of prescription of GV doses was retrospectively analysed before and after implementing the DB scheme. Four dose-ranges or ‘bands’ and the corresponding standard doses (250, 300, 350, 400 mg) were identified. Th…

GanciclovirCytotoxic drugSterilityDrug CompoundingDrug StorageGrowth promotion030226 pharmacology & pharmacyAntiviral AgentsStandard PreparationsExtended storage03 medical and health sciences0302 clinical medicineAnimal scienceDrug StabilityRefrigerationMedicineInfusions Parenteral030212 general & internal medicineGeneral Pharmacology Toxicology and PharmaceuticsGanciclovirDrug PackagingRetrospective StudiesOriginal Researchbusiness.industryReproducibility of ResultsRoboticsRobotic systemsAseptic processingbusinessDrug ContaminationPharmacy Service Hospitalmedicine.drugEuropean journal of hospital pharmacy : science and practice
researchProduct